Bet Inhibitor Rg6146, Venetoclax, and Rituximab Is a Highly Active Regimen in Relapsed/Refractory (R/R) Dlbcl: Initial Report of Phase 1b Safety, Biomarker, and Response Data

Hematological Oncology - United Kingdom
doi 10.1002/hon.131_2629
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

R-Ivac Salvage Therapy in Relapsed and Refractory DLBCL

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

VENETOCLAX (VEN), BENDAMUSTINE (B) AND RITUXIMAB (R) IN PATIENTS (PTS) WITH RELAPSED OR REFRACTORY (R/R) NON-HODGKIN LYMPHOMA (NHL): FINAL RESULTS OF a PHASE I STUDY

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Phase 1b Study of Venetoclax-Obinutuzumab in Previously Untreated and Relapsed/Refractory Chronic Lymphocytic Leukemia

Blood
BiochemistryImmunologyCell BiologyHematology
2019English

Real-World Bendamustine Use in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R Dlbcl)

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

PHASE 1B STUDY OF ViPOR (VENETOCLAX, IBRUTINIB, PREDNISONE, OBINUTUZUMAB, LENALIDOMIDE) IN RELAPSED/REFRACTORY B-Cell LYMPHOMA: SAFETY, EFFICACY AND MOLECULAR ANALYSIS

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Safety and Efficacy of Venetoclax Combined With Rituximab, Ifosfamide, Carboplatin and Etoposide (Vicer) for Treatment of Relapsed Dlbcl: Final Results From the Phase 1trial

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

The PI3Kδ INHIBITOR ME-401 ± RITUXIMAB IN RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL), CHRONIC LYMPHOCYTIC LEUKEMIA (CLL), AND SMALL LYMPHOCYTIC LYMPHOMA (SLL)

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Safety and Early Data From a Phase Ii Trial of Pembrolizumab (Pem) and Entinostat (Ent) in Relapsed and Refractory (R/R) Hodgkin Lymphoma (Hl) and Follicular Lymphoma (Fl)

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

HEALTH-RELATED QUALITY OF LIFE (HRQoL) IN RELAPSED/REFRACTORY (R/R) INDOLENT NHL IN THE PHASE 3 AUGMENT TRIAL OF RITUXIMAB (R) PLUS LENALIDOMIDE (R2 ) VERSUS R PLUS PLACEBO

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy